Here are five updates on GI companies from the past week:
RedHill Biopharma reported positive study results concerning its irritable bowel syndrome with diarrhea drug Bekinda, yet investors sent the drugmaker's stock tumbling.
A study, published in Digestive Diseases and Sciences, analyzed the efficacy of Medial EarlySign's ColonFlag.
Valeant Pharmaceuticals sold its iNova Pharmaceuticals business to a company jointly owned by Pacific Equity Partners and The Carlyle Group for $930 million.
Landos Biopharma completed a series A financing round raising $10 million.
The FDA approved Bracco Diagnostics' Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.